For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
|Articles|April 27, 2020
Video: How I have been using telemedicine amid COVID-19
Advertisement
Melanie Denton Dombrowski, OD, MBA, FAAO, jumped into telemedicine within 1 day of the American Optometric Association’s (AOA) communication. Find out how it fits into her practice and hear about a few telemedicine cases.
Advertisement
Related to this article
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5